BD-Covered Stent for Benign Esophageal Strictures: a Safety and Feasibility Study

NCT ID: NCT03189927

Last Updated: 2017-06-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-01

Study Completion Date

2019-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A non-randomized prospective clinical, pilot study in a single centre assessing the safety and feasibility of the esophageal biodegradable covered stent for refractory benign esophageal strictures with or without fistulae

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A non-randomized prospective clinical, pilot study in a single centre assessing the safety and feasibility of the esophageal biodegradable covered stent for refractory benign esophageal strictures with or without fistulae. The follow-up will be 6 months form implantation. After 3 months a control endoscopy will take place to evaluate stent and degradation process.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Esophageal Stricture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BD-Covered stent

Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae

Group Type EXPERIMENTAL

BD-Covered esophageal stent

Intervention Type DEVICE

a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BD-Covered esophageal stent

a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of both genders
* Age ≥ 18 years
* Appropriate cultural level and understanding of the study
* Willingness to participate voluntarily in the study and give written informed consent
* Refractory benign esophageal stricture with or without fistulae, i.e. the patient has to pass a minimum of 2 and a maximum of 10 failed esophageal dilations to the minimal diameter of 15-mm, using a pneumatic balloon dilator or Savary bougie, not complicated by or malignancy.
* Ability to undergo periodic endoscopic follow-up.

Exclusion Criteria

* Pregnancy or breastfeeding
* Simultaneous participation in another clinical study
* Life expectancy of less than 12 months
* Malignant esophageal stricture
* Stenosis after laryngectomy, or if the distance between the upper edge of the stent is less than 2 cm from the upper esophageal sphincter
* Undergone an esophageal stent implantation before.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ELLA-CS , sro

INDUSTRY

Sponsor Role collaborator

Radboud University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bram Vermeulen, Drs.

Role: CONTACT

0611079557 ext. +31

Peter SiersemA, Dr.

Role: CONTACT

06 547 84 967 ext. +31

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL.59222.091.16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.